Meeting
2019 ASCO Annual Meeting
Crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase II clinical trial–Updated report on progression-free and overall survival.
Authors
Sebastian Yves Friedrich Michels
Lung Cancer Group Cologne, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Dept. for Internal Medicine, Cologne, Germany
Sebastian Yves Friedrich Michels , Jeremy Franklin , Bartomeu Massuti , Martin Sebastian , Hans-Ulrich Schildhaus , Enriqueta Felip , Christian Grohe , Delvys Rodriguez-Abreu , Helge Bischoff , Enric Carcereny , Jesús Corral , Anne-Marie C. Dingemans , Amelia Insa , Martin Reck , Sacha Rothschild , Egbert F. Smit , Mariano Provencio , Reinhard Büttner , Rafael Rosell , Juergen Wolf
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02183870
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9066)
DOI
10.1200/JCO.2019.37.15_suppl.9066
Abstract #
9066
Poster Bd #
389
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Genomic characterization of lung tumors and metastatic (Met) sites in advanced (Adv) NSCLC.
First Author: Melinda D Willard
Poster
2022 ASCO Annual Meeting
Crizotinib in ROS1-rearranged lung cancer (EUCROSS): Updated overall survival.
First Author: Sebastian Yves Friedrich Michels
Poster
2020 ASCO Virtual Scientific Program
TRIDENT-1: A global, multicenter, open-label Phase II study investigating the activity of repotrectinib in advanced solid tumors harboring ROS1 or NTRK1-3 rearrangements.
First Author: Robert Charles Doebele
Poster
2018 ASCO Annual Meeting
An amplicon-based liquid biopsy for detecting ALK and ROS1 fusions and resistance mutations in advanced non-small cell lung cancer (NSCLC) patients.
First Author: Laura Mezquita